MYIA
IMMU

Mount Yale Investment Advisors’s Immunomedics Inc IMMU Stock Holding History

Mount Yale Investment Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,573
Closed -$38K – 891
2018
Q3 		$38K Buy
+1,573
New +$37.3K 0.01% 661

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Mount Yale Investment Advisors's IMMU Position: Q4 2018 in Review

Mount Yale Investment Advisors sold out of Immunomedics Inc (IMMU) in Q4 2018, closing a stake of 1,573 shares — an estimated $38K sold.

Mount Yale Investment Advisors first reported a position in IMMU in Q3 2018 and held it in 1 quarter. The position peaked at $38K in Q3 2018. 205 funds tracked by Wall St. Rank hold IMMU as of Q4 2018.

  • Mount Yale Investment Advisors reported no remaining Immunomedics Inc position as of Q4 2018 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 1,573 Immunomedics Inc shares in Q4 2018, an estimated $38K.
  • Mount Yale Investment Advisors first reported a position in Immunomedics Inc in Q3 2018 and held it in 1 quarter.
  • Mount Yale Investment Advisors's Immunomedics Inc position peaked at $38K in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2018.

Based on Mount Yale Investment Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.